Press Releases

Gonorrhea Therapeutics Market at US$ 1.3 Bn in 2018 and is projected to expand at a CAGR of ~5% from 2019 to 2030

Gonorrhea Therapeutics Market – High Scope of Advancement with Curative Approach

Improved sensitivity of early diagnostic screening tools has highlighted grave concerns regarding the surge in gonorrhea incidences. As per a survey conducted by the Centers for Disease Control and Prevention, 555,608 cases of gonorrhea were reported in 2017, in the U.S., demonstrating an increase of 18.6% from 2009. These figures have hard-pressed the governments of numerous countries to take preventive and curative measures for relegating the prevalence of gonorrhea.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111934

According to the gonorrhea therapeutics market research report published by Transparency Market Research (TMR), women are more susceptible to this disease than men, and the number of women availing therapeutics is on an exponential increase, thereby making women the key demographic of the market. The scramble of market players towards addressing the issue at the grass-root level has engendered several vaccines, including 4CMenB and rLP2086, which harbingers steady growth prospects for the landscape. However, literatures claiming the progressive resistance of gonorrhea to therapeutics could surface uncertainties regarding market advancement.

‘Women More Susceptible to Gonorrhea than Men’, finds TMR Study

The connection of gonorrhea with infertility has accelerated the pace of research & development activities among market players to introduce effective therapeutics to combat this public health threat. A research team at the Louisiana State University Health Sciences discovered a novel antibiotic – zoliflodacin – to inhibit bacteria’s DNA synthesis with a differentiated approach than current antibiotics, which was well-received by the FDA, and the same has been marketed as an oral treatment for gonorrhea. Besides oral drugs, medical personnel recommend dual therapy over monotherapy, given the growing resistance of Neisseria Gonorrhoeae to antibiotics.

A majority of women with gonorrhea show subtle signs of ongoing damage to the uterine tract, which, if left untreated, could cause involuntary infertility, ectopic pregnancy, or even chronic pelvic pain. As a result, this TMR study identifies that, the number of women availing gonorrhea therapeutics is projected to rise at a CAGR of ~6% during 2019-2027, with uncomplicated gonococcal infection being the leading cause.

View full report@ https://qyresearchmedical.com/report/gonorrhea-therapeutics-market-gonococcal-infection-uncomplicated-gonococcal-infection-gonococcal-arthritis-gonococcal-meningitis-and-endocarditis-treatment-monotherapy-and-dual-therapy-route-of-administratio-019-2030/111934

Why Partnerships with Hospital Pharmacies Could be Profitable

The sales of gonorrhea therapeutics are projected to witness significant uptake from hospital pharmacies, as hospitals remain preferred care centers for patients diagnosed with gonorrhea. According to TMR’s estimates, hospital pharmacies will account for a value tantamount to ~US$ 548 Mn in 2019, out of which, ~37% of sales will come from hospital pharmacies based in North America alone.

Propitious environment for the growth of the healthcare sector in North America that is attributable to the intervention of the government in creating awareness regarding the prevalence of diseases, and hefty financial allocations for R&D activities are also likely to reflect on the advancement of the gonorrhea therapeutics market. Currently, North America monopolizes the gonorrhea therapeutics market; however, the Asia Pacific market holds profitable prospects on account of the growing sprawl of bacterial infections. On top of it, improvements in healthcare infrastructure coupled with financial lucidity of individuals has encouraged a large base to opt for effective gonorrhea therapeutics.

Analysts’ Viewpoint

Authors of the report opine that, the gonorrhea therapeutics market will rise from ~US$ 1.4 Bn in 2019 to ~US$ 2 Bn in 2027, representing a CAGR of ~5% during the forecast period, with the shifting paradigm from a preventive to curative healthcare approach. A heated competitive landscape in the global pharmaceutical vicinity is encouraging market players to penetrate into new markets to channelize the supply of therapeutics and consolidate their market position.

However, the same is not achieved only by forward integration but also by inorganic practices such as acquisitions, mergers, and collaborations, in order to establish distribution partnerships with regional and local players. For instance, AstraZeneca announced the acquisition of Takeda Pharmaceutical Company Limited to expand in regions with high growth potential. To add to that, market players can prioritize investments towards the development of vaccines to infiltrate into the market with a curative approach

Gonorrhea Therapeutics Market: Overview

The global gonorrhea therapeutics market is projected to be valued at ~US$ 1.4 Bn in 2019, and expand at a CAGR of ~5.3% from 2019 to 2027. The rising prevalence of the disease and increasing use of new diagnostic tests are key factors that fuel the global gonorrhea therapeutics market.

Gonorrhea is a sexually transmitted infection caused by a bacterium, and can be transmitted through sexual contact. All people who are sexually active may be at the risk of acquiring gonorrhea. Gonorrhea can infect the urethra (the tube that allows urine and semen to pass out of the body), cervix, rectum, throat, mouth, and eyes. Though, several people suffering from gonorrhea do not exhibit any symptoms.

If symptoms do occur, they usually appear one to seven days after an infection. Symptoms can include vaginal pain, painful urination, and an abnormal discharge from the vagina, urethra, or rectum. Gonorrhea tests include obtaining samples from the sites of suspected infection and testing for the presence of the bacteria.

Gonorrhea can be treated and cured using antibiotics; however, some strains of gonorrhea have become resistant to a few antibiotics. Gonorrhea can increase the risk of the sexual transmission of HIV.

Gonorrhea can be transmitted through sexual intercourse. Transmission occurs when secretions from infected mucous membranes or semen of a person with a urethral infection come into contact with the mucous membranes of another person. Condom-less penetrative vaginal sex and anal sex are significantly high risk behaviors for the transmission of gonorrhea. Gonorrhea can be transmitted when a person who has an infection in the mouth or throat performs oral sex on another person, or when a person performs oral sex on a person who has a genital infection.

Global Gonorrhea Therapeutics Market: Drivers & Restraints

Rising Prevalence of Gonorrhea: Gonorrhea is the second-most commonly reported notifiable disease in the U.S. Infections due to Neisseria gonorrhea, such as those resulting from Chlamydia trachomatis, are a major cause of pelvic inflammatory disease (PID) in the U.S. Moreover, epidemiologic and biologic studies provide evidence that gonococcal infections facilitate the transmission of HIV infection.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111934/2900

Emergence of Antibiotic-Resistant Gonococcal Strain: CDC data highlights the rising resistance to one of the two antibiotics in the dual therapy for gonorrhea, a development that threatens the last remaining effective treatment for the disease. N. gonorrhea has progressively developed resistance to each of the antimicrobials used for the treatment of gonorrhea. Declining susceptibility to cefixime resulted in a change to the CDC treatment guidelines in 2015, so that dual therapy with ceftriaxone and azithromycin is presently the only CDC recommended treatment regimen for gonorrhea.

Global Gonorrhea Therapeutics Market: Segment Analysis

The global gonorrhea therapeutics market has been segmented based on gonococcal infection, treatment, route of administration, gender, distribution channel and region

In terms of gonococcal infection, the global gonorrhea therapeutics market has been classified into uncomplicated gonococcal infection, gonococcal arthritis, gonococcal meningitis, and endocarditis. In terms of treatment, the global gonorrhea therapeutics market has been classified into monotherapy and dual therapy. In terms of route of administration, the global gonorrhea therapeutics market has been classified into oral and injectable. In terms of gender, the global gonorrhea therapeutics market has been bifurcated into women and men.

The uncomplicated gonococcal infection segment is projected to dominate the gonorrhea therapeutics market by the end of 2019. It is projected to maintain its dominance during the forecast period too.

Based on distribution channel, the global gonorrhea therapeutics market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment is estimated to dominate the gonorrhea therapeutics market by the end of 2019.

Global Gonorrhea Therapeutics Market: Regional Segmentation

In terms of region, the global gonorrhea therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

North America dominated the global gonorrhea therapeutics market in 2018 due to the growing prevalence of STDs and rapid advances in healthcare infrastructure in the region.

According to a recent study by the World Health Organization, in the U.S. alone, ~1 million cases of gonorrhea are reported annually. Favorable reimbursement policies and government funding to numerous health organizations for the development of drug-resistant gonorrhea treatment are projected to remain the key drivers of the gonorrhea therapeutics market in the region.

Europe

The gonorrhea therapeutics market in Europe is anticipated to expand at a considerable growth rate in the near future, owing to the increasing incidence of gonococcal infection in the region. Gonorrhea is the second-most notified sexually transmitted infection in Europe, after chlamydia.

Asia Pacific

The gonorrhea therapeutics market in Asia Pacific is projected to expand at a notable CAGR during the forecast period, due to a large patient pool and rise in investments in healthcare in countries such as China in the region.

Global Gonorrhea Therapeutics Market: Major Players

Key players operating in the global gonorrhea therapeutics market include

  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • Pfizer Inc
  • AstraZeneca
  • Hologic, Inc.
  • Danaher
  • Abbott
  • Becton Dickinson and Company
  • F. Hoffmann-La Roche Ltd.

These players are adopting strategies such as new product development, partnerships, and acquisitions to remain competitive in the global gonorrhea therapeutics market.

Gonorrhea Therapeutics Market – Key Questions Answered

  • What are the recent developments and market shifts observed in the gonorrhea therapeutics market?
  • What are the key winning imperatives for leading and prominent players functioning in the gonorrhea therapeutics market?
  • What are the significant trends stimulating the growth of the gonorrhea therapeutics market?
  • Which distribution channel will draw significant sales in the gonorrhea therapeutics market?

Gonorrhea Therapeutics Market – Segmentation

Gonococcal Infection

  • Uncomplicated Gonococcal Infection
  • Gonococcal Arthritis
  • Gonococcal Meningitis and Endocarditis

Treatment

  • Monotherapy
  • Dual Therapy

Route of Administration

  • Oral
  • Injectable

Gender

  • Women
  • Men

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gonorrhea Therapeutics Market 

4. Market Overview

4.1. Introduction

4.1.1. Gonococcal Infection Type Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Gonorrhea Therapeutics Market Analysis and Forecast, 2017–2030

4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

5.1. Regulatory Scenario by Region/globally

5.2. Reimbursement Scenario by Region/globally

6. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Gonococcal Infection Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Gonorrhea Therapeutics Market Forecast, by Gonococcal Infection Type, 2017–2030

6.3.1. Uncomplicated Gonococcal Infection

6.3.2. Gonococcal Arthritis

6.3.3. Gonococcal Meningitis and Endocarditis

6.4. Global Gonorrhea Therapeutics Market Attractiveness, by Gonococcal Infection Type

7. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Treatment

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global Gonorrhea Therapeutics Market Forecast, by Treatment, 2017–2030

7.3.1. Monotherapy

7.3.2. Dual Therapy

7.4. Global Gonorrhea Therapeutics Market Attractiveness, by Treatment

8. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Route of Administration

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Global Gonorrhea Therapeutics Market Forecast, by Route of Administration, 2017–2030

8.3.1. Oral

8.3.2. Injectable

8.4. Global Gonorrhea Therapeutics Market Attractiveness, by Route of Administration

9. Global Gonorrhea Therapeutics Market Analysis and Forecast, by Gender

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Global Gonorrhea Therapeutics Market Forecast, by Gender, 2017–2030

9.3.1. Women

9.3.2. Men

9.4. Global Gonorrhea Therapeutics Market Attractiveness, by Gender

10.  Global Gonorrhea Therapeutics Market Analysis and Forecast, by Distribution Channel

……

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111934/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button